Fusion Antibodies (FAB)

Sector:

Health Care

Index:

FTSE AIM All-Share

 14.75p
   
  • Change Today:
      0.000p
  • 52 Week High: 17.50
  • 52 Week Low: 2.95
  • Currency: UK Pounds
  • Shares Issued: 113.66m
  • Volume: 1,144,780
  • Market Cap: £16.76m
  • RiskGrade: 464
  • Beta: 0.02

Latest ShareCast News

Fusion Antibodies selected for follow-on projects

By Iain Gilbert

Date: Wednesday 27 Aug 2025

(Sharecast News) - Pre-clinical antibody discovery specialists Fusion Antibodies said on Wednesday that it has been selected for three follow-on projects to its existing stable Cell Line Development project.

Fusion Antibodies validation project with US NIC progresses

By Josh White

Date: Friday 31 Jan 2025

(Sharecast News) - Fusion Antibodies announced on Friday that its OptiMAL validation project with the US National Cancer Institute (NCI) was progressing as planned.

Fusion Antibodies reports positive recent trading

By Josh White

Date: Tuesday 08 Oct 2024

(Sharecast News) - Fusion Antibodies reported positive trading in an update on Tuesday, highlighting significant progress for the first half of its financial year.

Fusion Antibodies strengthens financial position... 05-Sep-2024 ShareCast
Fusion Antibodies 'on track and on plan' followi... 04-Jul-2024 ShareCast
Fusion Antibodies gets first order under new ser... 27-Feb-2024 ShareCast
Fusion Antibodies raises £1.38m as it seeks new ... 14-Feb-2024 ShareCast
Fusion Antibodies confirms £0.28m tax credit 01-Feb-2024 ShareCast
Fusion Antibodies revenue falls, losses widen in... 04-Dec-2023 ShareCast
Fusion Antibodies appoints interim finance chief 24-Aug-2023 ShareCast
Fusion Antibodies progresses AI antibody collabo... 21-Aug-2023 ShareCast
Contract suspensions see Fusion Antibodies warn ... 06-Mar-2023 ShareCast
Fusion Antibodies confident after 'challenging' ... 05-Dec-2022 ShareCast
Fusion Antibodies reports strong full-year reven... 06-May-2022 ShareCast
Fusion Antibodies forms new scientific advisory ... 14-Jan-2022 ShareCast
Revenues rise, losses widen for Fusion Antibodies 06-Dec-2021 ShareCast
Fusion Antibodies signs collaborative deal with ... 07-Oct-2021 ShareCast
Fusion Antibodies performing in line in year-to-... 24-Sep-2021 ShareCast
Revenues rise, losses widen for Fusion Antibodies 10-Aug-2021 ShareCast
Fusion Antibodies receives first research milest... 23-Jul-2021 ShareCast
 

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

FAB Market Data

Currency UK Pounds
Share Price 14.75p
Change Today 0.000p
% Change 0.00 %
52 Week High 17.50
52 Week Low 2.95
Volume 1,144,780
Shares Issued 113.66m
Market Cap £16.76m
Beta 0.02
RiskGrade 464

FAB Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
55.52% below the market average55.52% below the market average55.52% below the market average55.52% below the market average55.52% below the market average
39.39% below the sector average39.39% below the sector average39.39% below the sector average39.39% below the sector average39.39% below the sector average
Price Trend
96.67% above the market average96.67% above the market average96.67% above the market average96.67% above the market average96.67% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Income Not Available
Growth
26.15% below the market average26.15% below the market average26.15% below the market average26.15% below the market average26.15% below the market average
20% below the sector average20% below the sector average20% below the sector average20% below the sector average20% below the sector average

FAB Dividends

No dividends found

Trades for 28-Aug-2025

Time Volume / Share Price
16:29 8 @ 14.90p
16:27 2 @ 14.90p
15:10 70,000 @ 15.30p
16:10 10,000 @ 14.51p
16:06 10 @ 15.00p

FAB Key Personnel

Chair Simon Gordon Douglas
CEO Adrian Kinkaid

Top of Page